Agila chief among highest-paid execs in India; J&J to pay $600K in first hip implant settlements;

 @FiercePharma: TNF inhibitors-Enbrel, Remicade, Humira, etc.--may actually lower heart attack risks in psoriasis patients. More | Follow @FiercePharma

> India's Agila Specialties, a unit of Strides Arcolab said to be on the block, paid its CEO enough last year to put him among the highest-paid executives in India. Report

> Johnson & Johnson ($JNJ) agreed to pay about $600,000 to settle three cases over hip implants recalled in 2010, the first among thousands of patient lawsuits it faces. Report

> Pfizer ($PFE) has to sort out a host of manufacturing questions as it prepares to spin off the animal health unit Zoetis, including which Pfizer sites will continue to turn out the unit's products. Report

> Johnson & Johnson CEO William Weldon will serve on the JPMorgan Chase committee investigating the derivative trades that spawned $5.8 billion in losses this year. Report

> Researchers advised the WHO to review a drug used to prevent life-threatening bleeding in childbirth, saying there's not enough evidence that it's effective. Report

> Watson Pharmaceuticals ($WPI) launched a knockoff version of Sunovion Pharmaceuticals' bronchospasm remedy Xopenex. Report

Medical Device News

@FierceMedDev: More trouble for St. Jude as study questions safety of Durata leads. Report | Follow @FierceMedDev

 @MarkHFierce: GE is among three investors who committed $20 million to Ornim, a maker of a non invasive blood flow/oxygen monitor. Release | Follow @MarkHFierce

 @DamianFierce: Maine's medical device middlemen fret over how impending 2.3% tax will cut into profits. More | Follow @DamianFierce

> General Electric invests in Israeli maker of blood monitoring device. News

> Medtronic posts 5% income boost despite CRM dip in Q1. More

> Discontinued St. Jude catheter finds new life at Vascular Solutions. Item

Biotech News

 @FierceBiotech: MediciNova snags $20M deal to finance R&D work. Item | Follow @FierceBiotech

 @JohnCFierce: Kineta uses unorthodox strategy to push autoimmune drug into clinic--my take on an unusual approach to drug development. Editor's Corner | Follow @JohnCFierce

 @RyanMFierce: Closer to mainstream media, Fast Company mag caught up with Sanofi's social strategy for diabetes. More | Follow @RyanMFierce

> Controversial stem cell treatment put to test in groundbreaking autism study. Article

> Buzz: Genomics startup Halcyon Molecular tanks. More

> FDA pushes back PDUFA date on crucial Pfizer app for tofacitinib. Story

> Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline. News

Pharma Manufacturing News

> Roche CEO says Genentech has resolved Perjeta production problems. Story

> $19M Cambrex plant expansion to benefit manufacturer and local community. News

> GSK closes 50-year-old India plant, 'retires' 330. Report

> API growth to spurt in Central, South America. More

Biotech Research News

> Old antifungal drug also fights tumors, researchers discover. Article

> Scientists discover wound-healing secret. Story

> A cool $1M to fund preclinical work on nanotech/siRNA cancer drug. More

> Dana-Farber, Broad Institute spot CYCLOPS gene class in cancer fight. New

And Finally... Newer psoriasis drugs may lower heart attack risks for patients. Report

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.